A citation-based method for searching scientific literature


List of co-cited articles
1446 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
483
50

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
Theresa R Bomfim, Leticia Forny-Germano, Luciana B Sathler, Jordano Brito-Moreira, Jean-Christophe Houzel, Helena Decker, Michael A Silverman, Hala Kazi, Helen M Melo, Paula L McClean,[...]. J Clin Invest 2012
601
34

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease.
Andre F Batista, Leticia Forny-Germano, Julia R Clarke, Natalia M Lyra E Silva, Jordano Brito-Moreira, Susan E Boehnke, Andrew Winterborn, Brian C Coe, Ann Lablans, Juliana F Vital,[...]. J Pathol 2018
136
34

In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
225
33

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
Konrad Talbot, Hoau-Yan Wang, Hala Kazi, Li-Ying Han, Kalindi P Bakshi, Andres Stucky, Robert L Fuino, Krista R Kawaguchi, Andrew J Samoyedny, Robert S Wilson,[...]. J Clin Invest 2012
31

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection.
Matthew J During, Lei Cao, David S Zuzga, Jeremy S Francis, Helen L Fitzsimons, Xiangyang Jiao, Ross J Bland, Matthias Klugmann, William A Banks, Daniel J Drucker,[...]. Nat Med 2003
610
28


The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer's Disease.
Henrik H Hansen, Katrine Fabricius, Pernille Barkholt, Michael L Niehoff, John E Morley, Jacob Jelsing, Charles Pyke, Lotte Bjerre Knudsen, Susan A Farr, Niels Vrang. J Alzheimers Dis 2015
110
27


The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
Caitriona M Long-Smith, Sean Manning, Paula L McClean, Meghan F Coakley, Domhnall J O'Halloran, Christian Holscher, Cora O'Neill. Neuromolecular Med 2013
115
24


Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes?
Eric Steen, Benjamin M Terry, Enrique J Rivera, Jennifer L Cannon, Thomas R Neely, Rose Tavares, X Julia Xu, Jack R Wands, Suzanne M de la Monte. J Alzheimers Dis 2005
23

DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease.
Yue Cao, Christian Hölscher, Meng-Ming Hu, Ting Wang, Fang Zhao, Yu Bai, Jun Zhang, Mei-Na Wu, Jin-Shun Qi. Eur J Pharmacol 2018
41
53

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
375
22

GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease.
Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis,[...]. J Alzheimers Dis 2010
234
21

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.
Steven E Arnold, Zoe Arvanitakis, Shannon L Macauley-Rambach, Aaron M Koenig, Hoau-Yan Wang, Rexford S Ahima, Suzanne Craft, Sam Gandy, Christoph Buettner, Luke E Stoeckel,[...]. Nat Rev Neurol 2018
585
21

Exenatide and the treatment of patients with Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Peter Ell, Therese Soderlund, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Clin Invest 2013
299
21

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Grazia Daniela Femminella, Eleni Frangou, Sharon B Love, Gail Busza, Clive Holmes, Craig Ritchie, Robert Lawrence, Brady McFarlane, George Tadros, Basil H Ridha,[...]. Trials 2019
87
24

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain.
Simon C Cork, James E Richards, Marie K Holt, Fiona M Gribble, Frank Reimann, Stefan Trapp. Mol Metab 2015
244
20





Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats.
H-Y Cai, C Hölscher, X-H Yue, S-X Zhang, X-H Wang, F Qiao, W Yang, J-S Qi. Neuroscience 2014
64
28


Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
179
17


Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease.
Hong-Yan Cai, Jun-Ting Yang, Zhao-Jun Wang, Jun Zhang, Wei Yang, Mei-Na Wu, Jin-Shun Qi. Biochem Biophys Res Commun 2018
53
32

Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial.
Suzanne Craft, Laura D Baker, Thomas J Montine, Satoshi Minoshima, G Stennis Watson, Amy Claxton, Matthew Arbuckle, Maureen Callaghan, Elaine Tsai, Stephen R Plymate,[...]. Arch Neurol 2012
850
17

Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.
Kathleen T Watson, Tonita E Wroolie, Gabby Tong, Lara C Foland-Ross, Sophia Frangou, Manpreet Singh, Roger S McIntyre, Siena Roat-Shumway, Alison Myoraku, Allan L Reiss,[...]. Behav Brain Res 2019
54
31

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.
Wei-Na Han, Christian Hölscher, Li Yuan, Wei Yang, Xiao-Hui Wang, Mei-Na Wu, Jin-Shun Qi. Neurobiol Aging 2013
106
16

Neuroinflammation in Alzheimer's disease.
Michael T Heneka, Monica J Carson, Joseph El Khoury, Gary E Landreth, Frederic Brosseron, Douglas L Feinstein, Andreas H Jacobs, Tony Wyss-Coray, Javier Vitorica, Richard M Ransohoff,[...]. Lancet Neurol 2015
16

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Henrik H Hansen, Katrine Fabricius, Pernille Barkholt, Pernille Kongsbak-Wismann, Chantal Schlumberger, Jacob Jelsing, Dick Terwel, Annelies Termont, Charles Pyke, Lotte Bjerre Knudsen,[...]. PLoS One 2016
30
53


Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
248
15


Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
Yan Yang, Jing Zhang, Delin Ma, Muxun Zhang, Shuhong Hu, Shiying Shao, Cheng-Xin Gong. J Alzheimers Dis 2013
77
18

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Peng Feng, Xiangjian Zhang, Dongfang Li, Chenhui Ji, Ziyue Yuan, Ruifang Wang, Guofang Xue, Guanglai Li, Christian Hölscher. Neuropharmacology 2018
60
23

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
417
14

TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.
Mychael V Lourenco, Julia R Clarke, Rudimar L Frozza, Theresa R Bomfim, Letícia Forny-Germano, André F Batista, Luciana B Sathler, Jordano Brito-Moreira, Olavo B Amaral, Cesar A Silva,[...]. Cell Metab 2013
264
14

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling.
Aileen M Moloney, Rebecca J Griffin, Suzanne Timmons, Rosemary O'Connor, Rivka Ravid, Cora O'Neill. Neurobiol Aging 2010
534
14

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
Paula L McClean, Victor A Gault, Patrick Harriott, Christian Hölscher. Eur J Pharmacol 2010
142
14

Blood-Brain Glucose Transfer in Alzheimer's disease: Effect of GLP-1 Analog Treatment.
Michael Gejl, Birgitte Brock, Lærke Egefjord, Kim Vang, Jørgen Rungby, Albert Gjedde. Sci Rep 2017
76
17

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
273
13

The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy.
Henrik H Hansen, Pernille Barkholt, Katrine Fabricius, Jacob Jelsing, Dick Terwel, Charles Pyke, Lotte Bjerre Knudsen, Niels Vrang. Brain Res 2016
54
24



GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Olivia M Farr, Michail Sofopoulos, Michael A Tsoukas, Fadime Dincer, Bindiya Thakkar, Ayse Sahin-Efe, Andreas Filippaios, Jennifer Bowers, Alexandra Srnka, Anna Gavrieli,[...]. Diabetologia 2016
125
12

Entry of exendin-4 into brain is rapid but may be limited at high doses.
A J Kastin, V Akerstrom. Int J Obes Relat Metab Disord 2003
264
12

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
Ziyue Yuan, Dongfang Li, Peng Feng, Guofang Xue, Chenhui Ji, Guanglai Li, Christian Hölscher. Eur J Pharmacol 2017
61
19


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.